- Home
- HE vs MRVI Comparison
HE vs MRVI Comparison
Compare HE & MRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HE
- MRVI
- Stock Information
- Founded
- HE 1891
- MRVI 2014
- Country
- HE United States
- MRVI United States
- Employees
- HE N/A
- MRVI N/A
- Industry
- HE Electric Utilities: Central
- MRVI Biotechnology: Pharmaceutical Preparations
- Sector
- HE Utilities
- MRVI Health Care
- Exchange
- HE Nasdaq
- MRVI Nasdaq
- Market Cap
- HE 1.9B
- MRVI 312.4M
- IPO Year
- HE N/A
- MRVI 2020
- Fundamental
- Price
- HE $10.62
- MRVI $2.58
- Analyst Decision
- HE Hold
- MRVI Hold
- Analyst Count
- HE 4
- MRVI 10
- Target Price
- HE $10.94
- MRVI $6.84
- AVG Volume (30 Days)
- HE 1.8M
- MRVI 2.0M
- Earning Date
- HE 08-07-2025
- MRVI 08-06-2025
- Dividend Yield
- HE N/A
- MRVI N/A
- EPS Growth
- HE N/A
- MRVI N/A
- EPS
- HE N/A
- MRVI N/A
- Revenue
- HE $3,171,906,000.00
- MRVI $241,856,000.00
- Revenue This Year
- HE $23.08
- MRVI N/A
- Revenue Next Year
- HE $1.74
- MRVI $10.62
- P/E Ratio
- HE N/A
- MRVI N/A
- Revenue Growth
- HE 0.66
- MRVI N/A
- 52 Week Low
- HE $8.14
- MRVI $1.67
- 52 Week High
- HE $18.19
- MRVI $10.03
- Technical
- Relative Strength Index (RSI)
- HE 51.85
- MRVI 58.53
- Support Level
- HE $10.49
- MRVI $2.63
- Resistance Level
- HE $10.80
- MRVI $2.93
- Average True Range (ATR)
- HE 0.30
- MRVI 0.18
- MACD
- HE -0.01
- MRVI 0.02
- Stochastic Oscillator
- HE 41.18
- MRVI 65.19
About HE Hawaiian Electric Industries Inc.
Hawaiian Electric Industries is the parent company of three Hawaii-based regulated utilities and owns a 10% minority interest in Hawaii's American Savings Bank. The utilities provide electricity on the five islands of Oahu, Hawaii, Maui, Molokai, and Lanai.
About MRVI Maravai LifeSciences Holdings Inc.
Maravai LifeSciences Holdings Inc is a life sciences company that provides critical products that drive the development of groundbreaking vaccines, drug therapies, cell and gene therapies, and diagnostics. The group's solutions empower research into human diseases and support the entire biopharmaceutical development process from early discovery to commercialization. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.